EGFR and cancer: Mutations in EGFR and KRAS might be two different ways of conferring cancer phenotypes, but simultaneous mutations in both the genes might be non-optimal for cancer cell survival, and in this way, mutations in EGFR and KRAS are synthetic lethal.